{"gene":"MS4A4A","run_date":"2026-04-28T18:30:28","timeline":{"discoveries":[{"year":2001,"finding":"MS4A4A was identified as a member of the membrane-spanning 4A (MS4A) gene family, sharing four transmembrane domains with N- and C-terminal cytoplasmic domains, clustered on chromosome 11q12-13. The family members were proposed to function as components of oligomeric cell-surface complexes involved in signal transduction.","method":"cDNA cloning, northern blot, genomic mapping","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 — structural characterization by cloning and expression analysis; foundational family identification replicated across two independent groups","pmids":["11401424","11245982","11486273"],"is_preprint":false},{"year":2015,"finding":"MS4A4A (referred to as MS4A4 in mast cells) facilitates trafficking of the receptor tyrosine kinase KIT through endocytic recycling rather than degradation pathways by recruiting KIT to caveolin-1-enriched microdomains. Silencing MS4A4A in human mast cells shifted KIT toward degradation, reduced receptor recycling to the cell surface, altered Akt and PLCγ1 phosphorylation compartmentalization, and increased SCF-induced mast cell proliferation and migration.","method":"siRNA silencing in human mast cells, endocytic trafficking assays, immunofluorescence colocalization, western blot for Akt and PLCγ1 phosphorylation, proliferation and migration assays","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 — clean KD with multiple orthogonal functional readouts (trafficking, signaling, proliferation, migration) in primary human cells","pmids":["25717186"],"is_preprint":false},{"year":2019,"finding":"MS4A4A interacts and colocalizes with the β-glucan receptor dectin-1 in lipid rafts on macrophages. Ms4a4a-deficient macrophages showed defective dectin-1-dependent signaling and defective production of effector molecules. In vivo, Ms4a4a deficiency impaired dectin-1-mediated macrophage activation required for NK cell-mediated resistance to metastasis, without affecting primary tumor growth.","method":"Co-immunoprecipitation, colocalization in lipid rafts, Ms4a4a knockout mouse model, dectin-1 ligand stimulation assays, tumor metastasis models, NK cell functional assays","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP, lipid raft fractionation, in vivo KO with defined pathway (dectin-1 → NK cell activation), replicated across murine and human systems","pmids":["31263276"],"is_preprint":false},{"year":2019,"finding":"MS4A4A colocalizes with TREM2 on lipid rafts at the plasma membrane of human macrophages. Overexpression of MS4A4A increased soluble TREM2 (sTREM2) production, while silencing MS4A4A reduced sTREM2 levels, indicating MS4A4A positively modulates sTREM2 shedding.","method":"Overexpression and siRNA knockdown in human macrophages, colocalization imaging in lipid rafts, sTREM2 ELISA","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 2 — bidirectional manipulation (OE and KD) with defined molecular readout (sTREM2), replicated with genetic association data","pmids":["31413141"],"is_preprint":false},{"year":2020,"finding":"MS4A4A promotes FcεRI-mediated signaling in human mast cells by facilitating phosphorylation of PLCγ1, calcium flux, and degranulation. MS4A4A interacts with caveolin-1 and recruits both FcεRI and KIT into lipid rafts. Additionally, MS4A4A regulates Orai1-mediated store-operated Ca2+ entry (SOCE) downstream of calcium store release, selectively in FcεRI signaling but not MrgprX2 signaling.","method":"siRNA knockdown in human mast cells, calcium flux assays, degranulation assays, co-immunoprecipitation with caveolin-1, lipid raft fractionation, western blot for PLCγ1 phosphorylation, pharmacological inhibition of Orai1","journal":"Cellular signalling","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (co-IP, Ca2+ flux, degranulation, lipid raft fractionation) in primary human mast cells with pathway specificity demonstrated","pmids":["32240745"],"is_preprint":false},{"year":2020,"finding":"MS4A4A regulates expression of arginase 1 (Arg1) in macrophages under IL-4 stimulation, and controls eosinophil infiltration during house dust mite-induced lung allergic inflammation in mice, placing MS4A4A in the IL-4-driven alternative (M2) macrophage polarization pathway.","method":"Ms4a4a-deficient mice, intranasal house dust mite model, Arg1 expression analysis under IL-4 stimulation, eosinophil counts","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — KO mouse with defined in vivo phenotype, but limited mechanistic detail on how MS4A4A controls Arg1","pmids":["32589266"],"is_preprint":false},{"year":2023,"finding":"MS4A4A promotes M2 polarization of macrophages by activating the PI3K/AKT pathway and JAK/STAT6 pathway. In vivo blockade or genetic inhibition of MS4A4A reduced M2-TAM infiltration and exhausted T cells while increasing effector CD8+ T cell infiltration, thereby reshaping the tumor immune microenvironment.","method":"RNA sequencing, western blot for PI3K/AKT and JAK/STAT6 pathway components, MS4A4A blockade with monoclonal antibody, flow cytometry and mass cytometry of tumor-infiltrating immune cells, subcutaneous and orthotopic mouse tumor models","journal":"Gut","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (RNA-seq, western blot, in vivo KO and antibody blockade, flow/mass cytometry) with defined signaling pathways identified","pmids":["37507218"],"is_preprint":false},{"year":2023,"finding":"The protective AD-associated MS4A variant (rs1582763) increases MS4A4A expression and shifts a 'chemokine' microglial subpopulation to an interferon state, while the risk variant (rs6591561) suppresses MS4A4A expression and reduces this microglial subpopulation, identifying MS4A4A as the major regulator of this chemokine microglial substate.","method":"Single nucleus transcriptomics of human AD brain tissue from variant carriers, microglial subpopulation characterization","journal":"medRxiv","confidence":"Low","confidence_rationale":"Tier 4 — transcriptomic/snRNA-seq in human tissue; no direct functional manipulation of MS4A4A protein","pmids":["36798226"],"is_preprint":true},{"year":2025,"finding":"MS4A4A interacts with MS4A6A and protects it from degradation. MS4A6A in turn forms a complex with DAP12 (DNAX-activating protein of 12 kDa), blocking DAP12 co-receptor function and thereby negatively regulating TREM2 protein levels (both transmembrane and soluble forms) and other DAP12-associated receptors. MS4A4A thus acts as a post-transcriptional negative regulator of TREM2 through an indirect mechanism via MS4A6A–DAP12.","method":"CRISPR knockout and overexpression in macrophages and primary human microglia, MS4A4A-degrading antibodies in non-human primates and xenotransplantation amyloid model, co-immunoprecipitation of MS4A6A-DAP12 complex, TREM2 protein quantification (transmembrane and soluble), lysosomal function and phagocytosis assays","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal approaches (CRISPR KO, OE, degrading antibodies, co-IP, in vivo NHP and xenotransplantation), mechanistic pathway defined across multiple model systems","pmids":["41435829"],"is_preprint":false},{"year":2025,"finding":"MS4A4A deletion in microglia impairs phagocytosis, accompanied by diminished calcium influx and disruptions in mitochondrial metabolic fitness. The cytosolic fragment of MS4A4A anchors to cytoskeletal components, supporting a structural role in mediating phagocytosis. Induction of Ms4a4a via central LNP-Il4 delivery alleviated seizure conditions in an Aβ-driven AD mouse model.","method":"Ms4a4a knockout mouse (5xFAD model), microglial phagocytosis assays, calcium flux measurements, mitochondrial metabolic assays, cytoskeletal interaction studies, LNP-Il4 central delivery rescue experiment, single-cell sequencing","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 — KO mouse with multiple functional readouts (phagocytosis, Ca2+ flux, mitochondria, cytoskeletal anchoring), but cytoskeletal interaction is single method","pmids":["40349168"],"is_preprint":false},{"year":2025,"finding":"Ms4a4a loss in 5xFAD mice reduces steady-state Aβ levels, shortens Aβ half-life in brain interstitial fluid, increases plaque compaction, and reduces plaque burden. Microglia lacking Ms4a4a exhibit a pro-inflammatory profile and elevated MMP-9 production, which may facilitate Aβ degradation. Human carriers of the AD-resilient MS4A4A variant rs1582763 also show elevated CSF MMP-9.","method":"5xFAD Ms4a4a knockout mouse model, in vivo microdialysis for Aβ half-life, plaque histology, microglial transcriptional profiling, MMP-9 ELISA in mouse and human CSF","journal":"Alzheimer's & dementia","confidence":"Medium","confidence_rationale":"Tier 2 — KO mouse with multiple mechanistic readouts (Aβ kinetics, MMP-9, microglial state) corroborated by human CSF data","pmids":["40843775"],"is_preprint":false},{"year":2025,"finding":"Corticosteroid (CS) treatment enhances MS4A4A expression in macrophages alongside FcγR3. In an experimental arthritis model, Ms4a4a deletion had no effect on disease course but was associated with enhanced therapeutic response specifically to corticosteroids, indicating MS4A4A counteracts CS therapeutic activity in the context of joint inflammation.","method":"In vitro CS treatment of human and murine macrophages (RNA-seq, immunohistochemistry), Ms4a4a knockout in experimental arthritis model with CS treatment, synovial biopsy analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 — KO mouse with drug-response phenotype plus in vitro mechanistic validation, but mechanism linking MS4A4A to CS resistance is not fully defined","pmids":["40924449"],"is_preprint":false}],"current_model":"MS4A4A is a tetraspan plasma membrane protein selectively expressed in macrophage-lineage cells and mast cells that functions as an organizer of lipid raft signaling complexes: it recruits dectin-1, FcεRI, KIT, and TREM2 into caveolin-1-enriched microdomains to promote downstream signaling (PLCγ1 phosphorylation, Ca2+ flux, degranulation, Arg1 induction, and M2 polarization via PI3K/AKT and JAK/STAT6); regulates KIT endocytic recycling; interacts with MS4A6A to protect it from degradation, thereby indirectly suppressing TREM2 via an MS4A6A–DAP12 complex; supports microglial phagocytosis through cytoskeletal anchoring and calcium influx; and modulates Aβ clearance in part through MMP-9 regulation."},"narrative":{"teleology":[{"year":2001,"claim":"Cloning of the MS4A gene family established MS4A4A as a four-transmembrane-domain protein within a chromosome 11q12-13 cluster, predicting a role in cell-surface signaling complexes but leaving its specific function unknown.","evidence":"cDNA cloning, northern blot, and genomic mapping in multiple cell types","pmids":["11401424","11245982","11486273"],"confidence":"Medium","gaps":["No binding partners or signaling pathway identified","Expression restricted to tissue-level surveys without single-cell resolution"]},{"year":2015,"claim":"The first mechanistic function was defined: MS4A4A routes KIT into caveolin-1-enriched endocytic recycling compartments in mast cells, preventing lysosomal degradation and compartmentalizing downstream Akt and PLCγ1 signaling.","evidence":"siRNA knockdown in primary human mast cells with endocytic trafficking assays, co-IP with caveolin-1, proliferation and migration readouts","pmids":["25717186"],"confidence":"High","gaps":["Mechanism of caveolin-1 interaction (direct vs. indirect) not resolved","Whether KIT trafficking role extends beyond mast cells untested"]},{"year":2019,"claim":"MS4A4A was shown to be a general lipid raft organizer for innate immune receptors: it recruits dectin-1 into lipid rafts on macrophages and separately colocalizes with TREM2, establishing two distinct receptor partnerships with different immunological consequences—antifungal/antimetastatic defense and sTREM2 shedding.","evidence":"Co-IP and lipid raft fractionation in macrophages; Ms4a4a KO mice challenged with tumor metastasis or dectin-1 ligands; overexpression/knockdown modulating sTREM2 in human macrophages","pmids":["31263276","31413141"],"confidence":"High","gaps":["Whether dectin-1 and TREM2 compete for MS4A4A binding unknown","Structural basis of MS4A4A–receptor interactions undefined","sTREM2 shedding enzyme identity in this context not established"]},{"year":2020,"claim":"MS4A4A was found to selectively potentiate FcεRI signaling—but not MrgprX2—by facilitating PLCγ1 phosphorylation and Orai1-mediated store-operated Ca²⁺ entry, and was placed in the IL-4/Arg1 M2 polarization axis in allergic lung inflammation.","evidence":"siRNA in human mast cells with Ca²⁺ flux, degranulation, and lipid raft assays; Ms4a4a KO mice in house dust mite allergy model with Arg1 expression analysis","pmids":["32240745","32589266"],"confidence":"High","gaps":["How MS4A4A discriminates FcεRI from MrgprX2 at the molecular level is unclear","Direct mechanism linking MS4A4A to Arg1 transcription not defined"]},{"year":2023,"claim":"MS4A4A was identified as a driver of M2 tumor-associated macrophage polarization through PI3K/AKT and JAK/STAT6, and its blockade reshaped the tumor immune microenvironment by reducing exhausted T cells and increasing effector CD8⁺ T cells.","evidence":"RNA-seq, western blot for PI3K/AKT and JAK/STAT6, antibody blockade and genetic inhibition in subcutaneous and orthotopic mouse tumor models with mass cytometry","pmids":["37507218"],"confidence":"High","gaps":["Whether MS4A4A directly activates PI3K or acts via an upstream receptor not resolved","Therapeutic window and specificity of anti-MS4A4A antibodies in vivo not fully characterized"]},{"year":2025,"claim":"A three-part mechanism was delineated: MS4A4A stabilizes MS4A6A, which forms a complex with DAP12 to suppress TREM2; MS4A4A loss or degradation therefore elevates TREM2 and enhances Aβ clearance, with MMP-9 as an additional effector for Aβ degradation, while MS4A4A's cytosolic domain anchors to the cytoskeleton to support phagocytic cup formation and Ca²⁺-dependent engulfment.","evidence":"CRISPR KO/OE in macrophages and human microglia, MS4A4A-degrading antibodies in NHP and xenotransplantation amyloid models, co-IP of MS4A6A–DAP12, 5xFAD Ms4a4a KO with in vivo microdialysis, MMP-9 ELISA in mouse and human CSF, cytoskeletal interaction studies, LNP-Il4 rescue","pmids":["41435829","40843775","40349168"],"confidence":"High","gaps":["Whether MS4A4A–MS4A6A interaction is direct or mediated by lipid raft proximity not resolved","Cytoskeletal binding domain within MS4A4A not mapped","Relative contribution of MMP-9 versus TREM2 elevation to Aβ clearance in humans unknown"]},{"year":2025,"claim":"MS4A4A was linked to corticosteroid resistance in macrophages: CS treatment induces MS4A4A, and Ms4a4a deletion enhances the therapeutic response to corticosteroids in experimental arthritis, revealing a pharmacologically relevant immunomodulatory axis.","evidence":"RNA-seq and IHC in CS-treated human and murine macrophages; Ms4a4a KO in experimental arthritis with CS treatment","pmids":["40924449"],"confidence":"Medium","gaps":["Molecular mechanism by which MS4A4A counteracts corticosteroid action not defined","Whether this extends to other inflammatory diseases unknown"]},{"year":null,"claim":"Key unresolved questions include the structural basis of MS4A4A's interactions with its diverse receptor partners, the identity of the sheddase responsible for MS4A4A-dependent sTREM2 release, and whether the opposing TREM2 regulatory modes (lipid raft colocalization promoting sTREM2 shedding versus MS4A6A–DAP12-mediated TREM2 suppression) operate simultaneously or in distinct cell states.","evidence":"","pmids":[],"confidence":"Low","gaps":["No high-resolution structural data for MS4A4A or its complexes","Sheddase identity for sTREM2 in the MS4A4A context unknown","Context-dependent switching between pro-TREM2 and anti-TREM2 functions not experimentally dissected"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[1,2,3,4,8]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,4,6,8]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,1,2,3,4]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,4,5,6,10,11]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,4,6]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[1]}],"complexes":[],"partners":["CAV1","CLEC7A","TREM2","KIT","MS4A6A","TYROBP","FCER1A"],"other_free_text":[]},"mechanistic_narrative":"MS4A4A is a tetraspanin-like membrane protein selectively expressed in macrophages, microglia, and mast cells that organizes receptor signaling by recruiting partners—dectin-1, FcεRI, KIT, and TREM2—into caveolin-1-enriched lipid raft microdomains, thereby coupling receptor engagement to PLCγ1 phosphorylation, store-operated Ca²⁺ entry, and downstream effector responses including degranulation, Arg1-dependent M2 polarization (via PI3K/AKT and JAK/STAT6), and phagocytosis [PMID:31263276, PMID:32240745, PMID:37507218, PMID:40349168]. MS4A4A governs KIT endocytic recycling versus degradation in mast cells, redirecting KIT to the cell surface through caveolin-1-positive compartments [PMID:25717186]. MS4A4A also stabilizes the paralog MS4A6A, which in turn complexes with DAP12 to suppress TREM2 protein levels; accordingly, MS4A4A degradation or loss elevates TREM2 and enhances microglial amyloid-β clearance, in part through increased MMP-9 production [PMID:41435829, PMID:40843775]. In tumor immunity, MS4A4A blockade reprograms M2-polarized tumor-associated macrophages, restoring effector CD8⁺ T cell infiltration and reducing T cell exhaustion [PMID:37507218]."},"prefetch_data":{"uniprot":{"accession":"Q96JQ5","full_name":"Membrane-spanning 4-domains subfamily A member 4A","aliases":["CD20 antigen-like 1","Four-span transmembrane protein 1"],"length_aa":239,"mass_kda":25.4,"function":"May be involved in signal transduction as a component of a multimeric receptor complex","subcellular_location":"Membrane","url":"https://www.uniprot.org/uniprotkb/Q96JQ5/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MS4A4A","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MS4A4A","total_profiled":1310},"omim":[{"mim_id":"608402","title":"MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 6E; MS4A6E","url":"https://www.omim.org/entry/608402"},{"mim_id":"608401","title":"MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 4E; MS4A4E","url":"https://www.omim.org/entry/608401"},{"mim_id":"606547","title":"MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 4A; MS4A4A","url":"https://www.omim.org/entry/606547"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"placenta","ntpm":59.3}],"url":"https://www.proteinatlas.org/search/MS4A4A"},"hgnc":{"alias_symbol":["CD20L1","MS4A7"],"prev_symbol":["MS4A4"]},"alphafold":{"accession":"Q96JQ5","domains":[{"cath_id":"-","chopping":"63-213","consensus_level":"high","plddt":87.9697,"start":63,"end":213}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96JQ5","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q96JQ5-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q96JQ5-F1-predicted_aligned_error_v6.png","plddt_mean":73.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MS4A4A","jax_strain_url":"https://www.jax.org/strain/search?query=MS4A4A"},"sequence":{"accession":"Q96JQ5","fasta_url":"https://rest.uniprot.org/uniprotkb/Q96JQ5.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q96JQ5/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96JQ5"}},"corpus_meta":[{"pmid":"31263276","id":"PMC_31263276","title":"The macrophage tetraspan MS4A4A enhances dectin-1-dependent NK cell-mediated resistance to metastasis.","date":"2019","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31263276","citation_count":115,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37507218","id":"PMC_37507218","title":"Targeting MS4A4A on tumour-associated macrophages restores CD8+ T-cell-mediated antitumour immunity.","date":"2023","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/37507218","citation_count":107,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28303902","id":"PMC_28303902","title":"MS4A4A: a novel cell surface marker for M2 macrophages and plasma cells.","date":"2017","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/28303902","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38478630","id":"PMC_38478630","title":"Hepatic danger signaling triggers TREM2+ macrophage induction and drives steatohepatitis via MS4A7-dependent inflammasome activation.","date":"2024","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38478630","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25717186","id":"PMC_25717186","title":"The CD20 homologue MS4A4 directs trafficking of KIT toward clathrin-independent endocytosis pathways and thus regulates receptor signaling and recycling.","date":"2015","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/25717186","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36944954","id":"PMC_36944954","title":"The short isoform of MS4A7 is a novel player in glioblastoma microenvironment, M2 macrophage polarization, and tumor progression.","date":"2023","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/36944954","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32240745","id":"PMC_32240745","title":"The FcεRIβ homologue, MS4A4A, promotes FcεRI signal transduction and store-operated Ca2+ entry in human mast cells.","date":"2020","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/32240745","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36798226","id":"PMC_36798226","title":"MS4A4A modifies the risk of Alzheimer disease by regulating lipid metabolism and immune response in a unique microglia state.","date":"2023","source":"medRxiv : the preprint server for health sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36798226","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32589266","id":"PMC_32589266","title":"MS4A4A Regulates Arginase 1 Induction during Macrophage Polarization and Lung Inflammation in Mice.","date":"2020","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32589266","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38997808","id":"PMC_38997808","title":"Targeting MS4A4A: A novel pathway to improve immunotherapy responses in glioblastoma.","date":"2024","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/38997808","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39954254","id":"PMC_39954254","title":"Lipid droplet efferocytosis attenuates proinflammatory signaling in macrophages via TREM2- and MS4A7-dependent mechanisms.","date":"2025","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/39954254","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40349168","id":"PMC_40349168","title":"Microglial MS4A4A Protects against Epileptic Seizures in Alzheimer's Disease.","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/40349168","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40522023","id":"PMC_40522023","title":"Role of MS4A7 in Regulating Microglial Polarization and Neuroinflammation in Spinal Cord Injury via the cGAS-STING-NLRP3 Axis.","date":"2025","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/40522023","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41231994","id":"PMC_41231994","title":"Ms4a7 expression in cDC1s determines cross-presentation and antitumor immunity.","date":"2025","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/41231994","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41435829","id":"PMC_41435829","title":"The Alzheimer's disease risk genes MS4A4A and MS4A6A cooperate to negatively regulate TREM2 and microglia states.","date":"2025","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/41435829","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40843775","id":"PMC_40843775","title":"Ms4a4a deficiency ameliorates plaque pathology in a mouse model of amyloid accumulation.","date":"2025","source":"Alzheimer's & dementia : the journal of the Alzheimer's Association","url":"https://pubmed.ncbi.nlm.nih.gov/40843775","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40924449","id":"PMC_40924449","title":"Synovial MS4A4A correlates with inflammation and counteracts response to corticosteroids in arthritis.","date":"2025","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/40924449","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41955527","id":"PMC_41955527","title":"Expression of MS4A4A on synovial infiltrating macrophages is a hallmark of rheumatoid arthritis and reflects disease severity.","date":"2026","source":"Immunological medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41955527","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.03.06.641917","title":"<i>Ms4a4a</i> deficiency ameliorates plaque pa thology in a mouse model of amyloid accumulation","date":"2025-03-10","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.06.641917","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.11.23.625001","title":"The Alzheimer’s Disease Risk Genes MS4A4A And MS4A6A Cooperate to Negatively Regulate Trem2 and Microglia states","date":"2024-11-24","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.23.625001","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.08.27.672693","title":"Sex and regional effects of <i>Bacteroides</i> in the gut","date":"2025-08-27","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.27.672693","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.03.26.645511","title":"A Single-Cell Atlas of RNA Alternative Splicing in the Glioma-Immune Ecosystem","date":"2025-03-30","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.26.645511","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":"21460841","id":"PMC_21460841","title":"Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.","date":"2011","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21460841","citation_count":1562,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"31413141","id":"PMC_31413141","title":"The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk.","date":"2019","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31413141","citation_count":228,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30833792","id":"PMC_30833792","title":"A protein-interaction network of interferon-stimulated genes extends the innate immune system landscape.","date":"2019","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30833792","citation_count":159,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11401424","id":"PMC_11401424","title":"Identification of a CD20-, FcepsilonRIbeta-, and HTm4-related gene family: sixteen new MS4A family members expressed in human and mouse.","date":"2001","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/11401424","citation_count":113,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11245982","id":"PMC_11245982","title":"Identification of a new multigene four-transmembrane family (MS4A) related to CD20, HTm4 and beta subunit of the high-affinity IgE receptor.","date":"2001","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/11245982","citation_count":83,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11486273","id":"PMC_11486273","title":"Structural organization of the human MS4A gene cluster on Chromosome 11q12.","date":"2001","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/11486273","citation_count":76,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23573206","id":"PMC_23573206","title":"Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23573206","citation_count":55,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23874341","id":"PMC_23874341","title":"Expression of MS4A and TMEM176 Genes in Human B Lymphocytes.","date":"2013","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23874341","citation_count":44,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16303743","id":"PMC_16303743","title":"Signal sequence and keyword trap in silico for selection of full-length human cDNAs encoding secretion or membrane proteins from oligo-capped cDNA libraries.","date":"2005","source":"DNA research : an international journal for rapid publication of reports on genes and genomes","url":"https://pubmed.ncbi.nlm.nih.gov/16303743","citation_count":43,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28005267","id":"PMC_28005267","title":"Human gingiva transcriptome during wound healing.","date":"2017","source":"Journal of clinical periodontology","url":"https://pubmed.ncbi.nlm.nih.gov/28005267","citation_count":41,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":12303,"output_tokens":2510,"usd":0.03728},"stage2":{"model":"claude-opus-4-6","input_tokens":5878,"output_tokens":2242,"usd":0.12816},"total_usd":0.37903,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":19138,"output_tokens":4689,"usd":0.063875},"round2_rules_fired":"R2","round2_stage2":{"model":"claude-opus-4-6","input_tokens":7157,"output_tokens":2561,"usd":0.149715}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2019,\n      \"finding\": \"MS4A4A physically interacts and colocalizes with the β-glucan receptor dectin-1 in lipid rafts on macrophages; Ms4a4a-deficient macrophages show defective dectin-1 signaling and defective production of effector molecules, and fail to support NK cell-mediated metastasis control.\",\n      \"method\": \"Co-localization, genetic knockout (Ms4a4a-deficient mice), signaling assays, experimental tumor/metastasis models\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-localization, KO with defined signaling and in vivo phenotype, replicated across murine and human systems\",\n      \"pmids\": [\"31263276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MS4A4A (referred to as MS4A4 in mast cells) directs KIT receptor trafficking toward caveolin-1-enriched microdomains and clathrin-independent endocytic recycling pathways; silencing MS4A4A shifts KIT toward degradation, increases endosomal KIT signaling (Akt phosphorylation), reduces plasma-membrane KIT signaling (PLCγ1 phosphorylation), and increases SCF-induced mast cell proliferation and migration.\",\n      \"method\": \"siRNA silencing, receptor trafficking assays, subcellular fractionation, phosphorylation assays, proliferation and migration assays in human mast cells\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (KD, fractionation, signaling assays, functional readouts) in a single study\",\n      \"pmids\": [\"25717186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MS4A4A promotes FcεRI-dependent PLCγ1 phosphorylation, store-operated Ca2+ entry (SOCE), and degranulation in human mast cells by interacting with caveolin-1 and recruiting FcεRI and KIT into lipid rafts; MS4A4A also regulates Orai1-mediated calcium entry downstream of calcium store release.\",\n      \"method\": \"Functional signaling assays (PLCγ1 phosphorylation, Ca2+ flux, degranulation), lipid raft fractionation, Orai1 interaction studies, selective stimulation comparisons in human mast cells\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal assays establishing mechanism in human primary cells\",\n      \"pmids\": [\"32240745\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MS4A4A regulates expression of arginase 1 in macrophages under IL-4 stimulation and controls eosinophil infiltration during house dust mite-induced lung allergic inflammation in mice.\",\n      \"method\": \"Ms4a4a-deficient mouse model, intranasal HDM allergen challenge, arginase 1 expression assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO with defined molecular (Arg1) and cellular phenotype, but single lab with limited mechanistic detail in abstract\",\n      \"pmids\": [\"32589266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"MS4A4A promotes M2 polarization of macrophages by activating the PI3K/AKT and JAK/STAT6 signaling pathways; in vivo blockade of MS4A4A reduces M2-TAM infiltration and increases effector CD8+ T cell infiltration in colorectal cancer models.\",\n      \"method\": \"RNA sequencing, western blot, flow cytometry, mass cytometry, in vivo antibody blockade and knockout tumor models\",\n      \"journal\": \"Gut\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO and antibody blockade with pathway-level mechanistic readouts (western blot PI3K/AKT, JAK/STAT6) and in vivo phenotype\",\n      \"pmids\": [\"37507218\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"MS4A4A interacts with MS4A6A and protects it from degradation; MS4A6A in turn forms a complex with and blocks the co-receptor DAP12, thereby indirectly suppressing TREM2 transmembrane and soluble protein levels and limiting microglia viability, phagocytosis, and lysosomal function.\",\n      \"method\": \"CRISPR knockout, overexpression, degrading antibodies, Co-IP/complex formation assays, primary human microglia, non-human primate and mouse amyloid models\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — complex formation demonstrated biochemically, validated across multiple model systems with functional readouts\",\n      \"pmids\": [\"41435829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Deletion of Ms4a4a in microglia impairs phagocytosis, reduces calcium influx, and disrupts mitochondrial metabolic fitness; the cytosolic fragment of Ms4a4a anchors to cytoskeletal components, supporting its role in mediating phagocytosis; Ms4a4a loss exacerbates epileptic seizures in an Aβ-driven AD mouse model.\",\n      \"method\": \"Ms4a4a knockout mice, 5xFAD AD model, single-cell sequencing, phagocytosis assays, calcium flux measurements, mitochondrial metabolic assays, cytoskeletal co-localization\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO with multiple mechanistic readouts (phagocytosis, Ca2+, metabolism, cytoskeletal interaction), single lab\",\n      \"pmids\": [\"40349168\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Ms4a4a loss in 5xFAD mice reduces steady-state Aβ levels, shortens Aβ half-life in brain interstitial fluid, increases plaque compaction, reduces plaque burden, and is associated with a pro-inflammatory microglial profile with elevated MMP-9 production that may facilitate Aβ degradation.\",\n      \"method\": \"Ms4a4a KO × 5xFAD mouse model, brain interstitial fluid microdialysis (Aβ half-life), plaque quantification, microglial phenotyping, MMP-9 measurement\",\n      \"journal\": \"Alzheimer's & dementia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO with mechanistic readouts (Aβ turnover, MMP-9), corroborated by human CSF data\",\n      \"pmids\": [\"40843775\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In an experimental arthritis model, Ms4a4a deletion enhances therapeutic response to corticosteroids; corticosteroids upregulate MS4A4A along with FcγR3 in macrophages, and this co-upregulation counteracts the therapeutic activity of corticosteroids.\",\n      \"method\": \"Ms4a4a KO mouse arthritis model, in vitro macrophage stimulation with corticosteroids, flow cytometry and gene expression analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO with defined pharmacological phenotype and in vitro mechanistic validation, single lab\",\n      \"pmids\": [\"40924449\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"MS4A4A protein is expressed at the plasma membrane of monocytes and is induced during monocyte-to-macrophage differentiation in the presence of IL-4 (M2 conditions) but not IFN-γ/LPS (M1 conditions); it is absent from granulocytes and lymphocytes but expressed in plasma cells.\",\n      \"method\": \"Monoclonal antibody generation, flow cytometry of human peripheral blood subsets, in vitro monocyte differentiation assays\",\n      \"journal\": \"Immunology and cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — direct localization by flow cytometry with functional-context differentiation experiments, moderate evidence\",\n      \"pmids\": [\"28303902\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MS4A4A is a plasma-membrane tetraspan protein selectively expressed in macrophage-lineage cells and mast cells that functions as a scaffold in lipid rafts/caveolin-1-enriched microdomains: it co-localizes with and amplifies dectin-1 signaling in macrophages, directs KIT receptor trafficking toward recycling rather than degradation in mast cells, promotes FcεRI-dependent PLCγ1 and store-operated calcium entry via interaction with caveolin-1 and Orai1, drives M2 macrophage polarization through PI3K/AKT and JAK/STAT6 pathways, and in microglia acts as a negative regulator of TREM2 by stabilizing MS4A6A, which in turn blocks DAP12, thereby limiting phagocytosis, lysosomal function, and Aβ clearance.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper first, then extract discoveries only from KEEP papers.\n\n**Classification:**\n\n- [1] PMID:31263276 — KEEP (MS4A4A in macrophages, dectin-1)\n- [2] PMID:37507218 — KEEP (MS4A4A in TAMs, PI3K/AKT, JAK/STAT6)\n- [3] PMID:28303902 — KEEP (MS4A4A expression/localization in macrophages)\n- [4] PMID:38478630 — EXCLUDE (MS4A7, not MS4A4A)\n- [5] PMID:25717186 — KEEP (MS4A4 in mast cells, KIT trafficking) — note: \"MS4A4\" in mast cells; context consistent with MS4A4A\n- [6] PMID:36944954 — EXCLUDE (MS4A7-s, not MS4A4A)\n- [7] PMID:32240745 — KEEP (MS4A4A in mast cells, FcεRI signaling)\n- [8] PMID:36798226 — KEEP (MS4A4A in microglia, AD variants) — preprint but has PMID; mechanistic content about chemokine microglia subpopulation\n- [9] PMID:32589266 — KEEP (MS4A4A regulates Arginase 1)\n- [10] PMID:38997808 — KEEP (MS4A4A in GBM TAMs, ferroptosis/M2 polarization)\n- [11] PMID:39954254 — EXCLUDE (MS4A7, not MS4A4A)\n- [12] PMID:40349168 — KEEP (MS4A4A in microglia, phagocytosis, calcium, cytoskeleton)\n- [13] PMID:40522023 — EXCLUDE (MS4A7, not MS4A4A)\n- [14] PMID:41231994 — EXCLUDE (Ms4a7 in cDC1s, not MS4A4A)\n- [15] PMID:41435829 — KEEP (MS4A4A/MS4A6A/TREM2/DAP12 mechanism)\n- [16] PMID:40843775 — KEEP (Ms4a4a KO, MMP-9, Aβ clearance)\n- [17] PMID:40924449 — KEEP (MS4A4A in RA macrophages, corticosteroids)\n- [18] PMID:41955527 — EXCLUDE (expression/biomarker study, no direct mechanism)\n- [19] bio_10.1101_2025.03.06.641917 — KEEP (preprint of PMID:40843775, same content)\n- [20] bio_10.1101_2024.11.23.625001 — KEEP (preprint of PMID:41435829, same content — peer-reviewed version exists, preprint adds detail)\n- [21] bio_10.1101_2025.08.27.672693 — EXCLUDE (Bacteroides study, ms4a4a only mentioned as marker)\n- [22] bio_10.1101_2025.03.26.645511 — EXCLUDE (MS4A7 AS in glioma, not MS4A4A)\n\n**Gene2pubmed additional papers:**\n- PMID:21460841 — EXCLUDE (GWAS association only)\n- PMID:12477932 — EXCLUDE (cDNA library, no mechanism)\n- PMID:32296183 — EXCLUDE (general interactome, no MS4A4A-specific mechanism)\n- PMID:21873635 — EXCLUDE (GO annotation methods)\n- PMID:15489334 — EXCLUDE (cDNA library)\n- PMID:31413141 — KEEP (MS4A4A colocalization with TREM2, modulation of sTREM2)\n- PMID:30833792 — EXCLUDE (ISG network, no MS4A4A-specific mechanism)\n- PMID:11401424 — KEEP (MS4A family identification, structural features)\n- PMID:11245982 — KEEP (MS4A family cloning, structural characterization)\n- PMID:11486273 — KEEP (MS4A gene cluster structure)\n- PMID:23573206 — EXCLUDE (GWAS/biomarker association)\n- PMID:23874341 — KEEP (MS4A4A oligomerization potential, expression)\n- PMID:16303743 — EXCLUDE (cDNA selection method)\n- PMID:28005267 — EXCLUDE (wound healing transcriptome, MS4A4A not mechanistically studied)\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"MS4A4A was identified as a member of the membrane-spanning 4A (MS4A) gene family, sharing four transmembrane domains with N- and C-terminal cytoplasmic domains, clustered on chromosome 11q12-13. The family members were proposed to function as components of oligomeric cell-surface complexes involved in signal transduction.\",\n      \"method\": \"cDNA cloning, northern blot, genomic mapping\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — structural characterization by cloning and expression analysis; foundational family identification replicated across two independent groups\",\n      \"pmids\": [\"11401424\", \"11245982\", \"11486273\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MS4A4A (referred to as MS4A4 in mast cells) facilitates trafficking of the receptor tyrosine kinase KIT through endocytic recycling rather than degradation pathways by recruiting KIT to caveolin-1-enriched microdomains. Silencing MS4A4A in human mast cells shifted KIT toward degradation, reduced receptor recycling to the cell surface, altered Akt and PLCγ1 phosphorylation compartmentalization, and increased SCF-induced mast cell proliferation and migration.\",\n      \"method\": \"siRNA silencing in human mast cells, endocytic trafficking assays, immunofluorescence colocalization, western blot for Akt and PLCγ1 phosphorylation, proliferation and migration assays\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KD with multiple orthogonal functional readouts (trafficking, signaling, proliferation, migration) in primary human cells\",\n      \"pmids\": [\"25717186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MS4A4A interacts and colocalizes with the β-glucan receptor dectin-1 in lipid rafts on macrophages. Ms4a4a-deficient macrophages showed defective dectin-1-dependent signaling and defective production of effector molecules. In vivo, Ms4a4a deficiency impaired dectin-1-mediated macrophage activation required for NK cell-mediated resistance to metastasis, without affecting primary tumor growth.\",\n      \"method\": \"Co-immunoprecipitation, colocalization in lipid rafts, Ms4a4a knockout mouse model, dectin-1 ligand stimulation assays, tumor metastasis models, NK cell functional assays\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP, lipid raft fractionation, in vivo KO with defined pathway (dectin-1 → NK cell activation), replicated across murine and human systems\",\n      \"pmids\": [\"31263276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MS4A4A colocalizes with TREM2 on lipid rafts at the plasma membrane of human macrophages. Overexpression of MS4A4A increased soluble TREM2 (sTREM2) production, while silencing MS4A4A reduced sTREM2 levels, indicating MS4A4A positively modulates sTREM2 shedding.\",\n      \"method\": \"Overexpression and siRNA knockdown in human macrophages, colocalization imaging in lipid rafts, sTREM2 ELISA\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — bidirectional manipulation (OE and KD) with defined molecular readout (sTREM2), replicated with genetic association data\",\n      \"pmids\": [\"31413141\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MS4A4A promotes FcεRI-mediated signaling in human mast cells by facilitating phosphorylation of PLCγ1, calcium flux, and degranulation. MS4A4A interacts with caveolin-1 and recruits both FcεRI and KIT into lipid rafts. Additionally, MS4A4A regulates Orai1-mediated store-operated Ca2+ entry (SOCE) downstream of calcium store release, selectively in FcεRI signaling but not MrgprX2 signaling.\",\n      \"method\": \"siRNA knockdown in human mast cells, calcium flux assays, degranulation assays, co-immunoprecipitation with caveolin-1, lipid raft fractionation, western blot for PLCγ1 phosphorylation, pharmacological inhibition of Orai1\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (co-IP, Ca2+ flux, degranulation, lipid raft fractionation) in primary human mast cells with pathway specificity demonstrated\",\n      \"pmids\": [\"32240745\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MS4A4A regulates expression of arginase 1 (Arg1) in macrophages under IL-4 stimulation, and controls eosinophil infiltration during house dust mite-induced lung allergic inflammation in mice, placing MS4A4A in the IL-4-driven alternative (M2) macrophage polarization pathway.\",\n      \"method\": \"Ms4a4a-deficient mice, intranasal house dust mite model, Arg1 expression analysis under IL-4 stimulation, eosinophil counts\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse with defined in vivo phenotype, but limited mechanistic detail on how MS4A4A controls Arg1\",\n      \"pmids\": [\"32589266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"MS4A4A promotes M2 polarization of macrophages by activating the PI3K/AKT pathway and JAK/STAT6 pathway. In vivo blockade or genetic inhibition of MS4A4A reduced M2-TAM infiltration and exhausted T cells while increasing effector CD8+ T cell infiltration, thereby reshaping the tumor immune microenvironment.\",\n      \"method\": \"RNA sequencing, western blot for PI3K/AKT and JAK/STAT6 pathway components, MS4A4A blockade with monoclonal antibody, flow cytometry and mass cytometry of tumor-infiltrating immune cells, subcutaneous and orthotopic mouse tumor models\",\n      \"journal\": \"Gut\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (RNA-seq, western blot, in vivo KO and antibody blockade, flow/mass cytometry) with defined signaling pathways identified\",\n      \"pmids\": [\"37507218\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The protective AD-associated MS4A variant (rs1582763) increases MS4A4A expression and shifts a 'chemokine' microglial subpopulation to an interferon state, while the risk variant (rs6591561) suppresses MS4A4A expression and reduces this microglial subpopulation, identifying MS4A4A as the major regulator of this chemokine microglial substate.\",\n      \"method\": \"Single nucleus transcriptomics of human AD brain tissue from variant carriers, microglial subpopulation characterization\",\n      \"journal\": \"medRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 — transcriptomic/snRNA-seq in human tissue; no direct functional manipulation of MS4A4A protein\",\n      \"pmids\": [\"36798226\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"MS4A4A interacts with MS4A6A and protects it from degradation. MS4A6A in turn forms a complex with DAP12 (DNAX-activating protein of 12 kDa), blocking DAP12 co-receptor function and thereby negatively regulating TREM2 protein levels (both transmembrane and soluble forms) and other DAP12-associated receptors. MS4A4A thus acts as a post-transcriptional negative regulator of TREM2 through an indirect mechanism via MS4A6A–DAP12.\",\n      \"method\": \"CRISPR knockout and overexpression in macrophages and primary human microglia, MS4A4A-degrading antibodies in non-human primates and xenotransplantation amyloid model, co-immunoprecipitation of MS4A6A-DAP12 complex, TREM2 protein quantification (transmembrane and soluble), lysosomal function and phagocytosis assays\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches (CRISPR KO, OE, degrading antibodies, co-IP, in vivo NHP and xenotransplantation), mechanistic pathway defined across multiple model systems\",\n      \"pmids\": [\"41435829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"MS4A4A deletion in microglia impairs phagocytosis, accompanied by diminished calcium influx and disruptions in mitochondrial metabolic fitness. The cytosolic fragment of MS4A4A anchors to cytoskeletal components, supporting a structural role in mediating phagocytosis. Induction of Ms4a4a via central LNP-Il4 delivery alleviated seizure conditions in an Aβ-driven AD mouse model.\",\n      \"method\": \"Ms4a4a knockout mouse (5xFAD model), microglial phagocytosis assays, calcium flux measurements, mitochondrial metabolic assays, cytoskeletal interaction studies, LNP-Il4 central delivery rescue experiment, single-cell sequencing\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse with multiple functional readouts (phagocytosis, Ca2+ flux, mitochondria, cytoskeletal anchoring), but cytoskeletal interaction is single method\",\n      \"pmids\": [\"40349168\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Ms4a4a loss in 5xFAD mice reduces steady-state Aβ levels, shortens Aβ half-life in brain interstitial fluid, increases plaque compaction, and reduces plaque burden. Microglia lacking Ms4a4a exhibit a pro-inflammatory profile and elevated MMP-9 production, which may facilitate Aβ degradation. Human carriers of the AD-resilient MS4A4A variant rs1582763 also show elevated CSF MMP-9.\",\n      \"method\": \"5xFAD Ms4a4a knockout mouse model, in vivo microdialysis for Aβ half-life, plaque histology, microglial transcriptional profiling, MMP-9 ELISA in mouse and human CSF\",\n      \"journal\": \"Alzheimer's & dementia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse with multiple mechanistic readouts (Aβ kinetics, MMP-9, microglial state) corroborated by human CSF data\",\n      \"pmids\": [\"40843775\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Corticosteroid (CS) treatment enhances MS4A4A expression in macrophages alongside FcγR3. In an experimental arthritis model, Ms4a4a deletion had no effect on disease course but was associated with enhanced therapeutic response specifically to corticosteroids, indicating MS4A4A counteracts CS therapeutic activity in the context of joint inflammation.\",\n      \"method\": \"In vitro CS treatment of human and murine macrophages (RNA-seq, immunohistochemistry), Ms4a4a knockout in experimental arthritis model with CS treatment, synovial biopsy analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse with drug-response phenotype plus in vitro mechanistic validation, but mechanism linking MS4A4A to CS resistance is not fully defined\",\n      \"pmids\": [\"40924449\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MS4A4A is a tetraspan plasma membrane protein selectively expressed in macrophage-lineage cells and mast cells that functions as an organizer of lipid raft signaling complexes: it recruits dectin-1, FcεRI, KIT, and TREM2 into caveolin-1-enriched microdomains to promote downstream signaling (PLCγ1 phosphorylation, Ca2+ flux, degranulation, Arg1 induction, and M2 polarization via PI3K/AKT and JAK/STAT6); regulates KIT endocytic recycling; interacts with MS4A6A to protect it from degradation, thereby indirectly suppressing TREM2 via an MS4A6A–DAP12 complex; supports microglial phagocytosis through cytoskeletal anchoring and calcium influx; and modulates Aβ clearance in part through MMP-9 regulation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"MS4A4A is a tetraspanin-like membrane scaffold selectively expressed in macrophage-lineage cells and mast cells that organizes receptor signaling platforms within lipid rafts and caveolin-1-enriched microdomains. In macrophages, MS4A4A physically associates with dectin-1 to enable β-glucan-triggered effector responses and NK cell-mediated metastasis control [PMID:31263276], and promotes M2 polarization through PI3K/AKT and JAK/STAT6 pathways, shaping tumor-associated macrophage infiltration and anti-tumor immunity [PMID:37507218]. In mast cells, MS4A4A directs KIT and FcεRI into lipid rafts, governing receptor trafficking fate, PLCγ1 phosphorylation, Orai1-mediated store-operated calcium entry, and degranulation [PMID:25717186, PMID:32240745]. In microglia, MS4A4A stabilizes MS4A6A, which blocks the TREM2 co-receptor DAP12 to suppress TREM2 levels and limit phagocytosis, lysosomal function, and amyloid-β clearance [PMID:41435829, PMID:40843775].\",\n  \"teleology\": [\n    {\n      \"year\": 2015,\n      \"claim\": \"The discovery that MS4A4A channels KIT receptor into caveolin-1-enriched microdomains and clathrin-independent recycling—rather than degradation—established MS4A4A as a membrane scaffold that controls receptor trafficking fate and compartmentalized signaling in mast cells.\",\n      \"evidence\": \"siRNA knockdown with receptor trafficking assays, subcellular fractionation, and phosphorylation readouts in human mast cells\",\n      \"pmids\": [\"25717186\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Direct structural basis for MS4A4A–caveolin-1 interaction not resolved\",\n        \"Whether MS4A4A similarly controls trafficking of other mast cell receptors unknown\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrating that MS4A4A protein is induced during IL-4-driven monocyte-to-macrophage differentiation but absent under M1 conditions resolved the cellular context of expression and linked the protein to M2/alternatively activated macrophage biology.\",\n      \"evidence\": \"Monoclonal antibody-based flow cytometry on human blood subsets and in vitro differentiation assays\",\n      \"pmids\": [\"28303902\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Transcriptional regulation of MS4A4A during M2 differentiation not defined\",\n        \"Functional consequence of MS4A4A induction in M2 macrophages was not tested\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showing that MS4A4A physically interacts with dectin-1 in lipid rafts and is required for dectin-1-dependent macrophage effector signaling and NK-mediated anti-metastatic immunity established MS4A4A as a critical co-receptor scaffold in innate immune sensing.\",\n      \"evidence\": \"Co-localization, Ms4a4a-KO mice, signaling assays, and experimental metastasis models in murine and human systems\",\n      \"pmids\": [\"31263276\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether MS4A4A directly binds dectin-1 or assembles via lipid raft proximity not distinguished\",\n        \"Other pattern-recognition receptors that may depend on MS4A4A scaffolding not surveyed\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Two studies extended the lipid-raft scaffold model: MS4A4A was shown to recruit FcεRI and KIT into rafts to enable PLCγ1 phosphorylation, Orai1-mediated store-operated calcium entry, and degranulation in mast cells, while in macrophages MS4A4A controlled arginase-1 expression and eosinophil infiltration during allergic inflammation.\",\n      \"evidence\": \"Calcium flux, degranulation, lipid-raft fractionation, and Orai1 interaction assays in human mast cells; Ms4a4a-KO HDM airway challenge model\",\n      \"pmids\": [\"32240745\", \"32589266\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Molecular basis of MS4A4A–Orai1 interaction not structurally resolved\",\n        \"Whether arginase-1 regulation is a direct transcriptional effect or secondary to altered signaling not determined\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identifying PI3K/AKT and JAK/STAT6 as downstream pathways through which MS4A4A drives M2 macrophage polarization provided a mechanistic link between MS4A4A expression and the tumor-immune microenvironment, as MS4A4A blockade reduced M2-TAM infiltration and enhanced CD8+ T cell responses.\",\n      \"evidence\": \"RNA-seq, western blot, flow cytometry, mass cytometry, in vivo antibody blockade and KO tumor models in colorectal cancer\",\n      \"pmids\": [\"37507218\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Upstream ligand or activation signal that triggers MS4A4A-dependent PI3K/AKT engagement unknown\",\n        \"Whether anti-MS4A4A antibodies work by blocking a specific interaction or destabilizing raft organization not clarified\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A series of 2025 studies revealed that MS4A4A operates in microglia as a negative regulator of TREM2 by stabilizing MS4A6A, which blocks DAP12; loss of Ms4a4a reduced Aβ levels and plaque burden in 5xFAD mice while impairing microglial phagocytosis and calcium influx, and in arthritis Ms4a4a deletion enhanced corticosteroid efficacy by removing Fc receptor co-upregulation.\",\n      \"evidence\": \"CRISPR KO, Co-IP, degrading antibodies in human microglia and NHP/mouse amyloid models; 5xFAD microdialysis and plaque quantification; arthritis KO model with corticosteroid treatment\",\n      \"pmids\": [\"41435829\", \"40843775\", \"40349168\", \"40924449\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether the MS4A4A–MS4A6A–DAP12 axis operates identically in peripheral macrophages as in microglia not tested\",\n        \"Relative contributions of phagocytic impairment versus MMP-9-mediated Aβ degradation upon Ms4a4a loss not resolved\",\n        \"Structural basis for MS4A4A stabilization of MS4A6A unknown\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A unifying structural and biophysical model explaining how MS4A4A selectively scaffolds diverse receptors (dectin-1, KIT, FcεRI, MS4A6A) within lipid rafts and how its cytosolic domain engages cytoskeletal and signaling effectors remains to be established.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No high-resolution structure of MS4A4A or any MS4A4A-containing complex exists\",\n        \"Direct versus indirect nature of many reported interactions (e.g., with Orai1, cytoskeletal elements) not resolved\",\n        \"Whether MS4A4A has intrinsic enzymatic or channel activity is untested\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 1, 2, 5]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1, 2, 9]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 3, 4, 8]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 2, 4, 5]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CLEC7A\",\n      \"KIT\",\n      \"FCER1A\",\n      \"CAV1\",\n      \"ORAI1\",\n      \"MS4A6A\",\n      \"TYROBP\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"MS4A4A is a tetraspanin-like membrane protein selectively expressed in macrophages, microglia, and mast cells that organizes receptor signaling by recruiting partners—dectin-1, FcεRI, KIT, and TREM2—into caveolin-1-enriched lipid raft microdomains, thereby coupling receptor engagement to PLCγ1 phosphorylation, store-operated Ca²⁺ entry, and downstream effector responses including degranulation, Arg1-dependent M2 polarization (via PI3K/AKT and JAK/STAT6), and phagocytosis [PMID:31263276, PMID:32240745, PMID:37507218, PMID:40349168]. MS4A4A governs KIT endocytic recycling versus degradation in mast cells, redirecting KIT to the cell surface through caveolin-1-positive compartments [PMID:25717186]. MS4A4A also stabilizes the paralog MS4A6A, which in turn complexes with DAP12 to suppress TREM2 protein levels; accordingly, MS4A4A degradation or loss elevates TREM2 and enhances microglial amyloid-β clearance, in part through increased MMP-9 production [PMID:41435829, PMID:40843775]. In tumor immunity, MS4A4A blockade reprograms M2-polarized tumor-associated macrophages, restoring effector CD8⁺ T cell infiltration and reducing T cell exhaustion [PMID:37507218].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Cloning of the MS4A gene family established MS4A4A as a four-transmembrane-domain protein within a chromosome 11q12-13 cluster, predicting a role in cell-surface signaling complexes but leaving its specific function unknown.\",\n      \"evidence\": \"cDNA cloning, northern blot, and genomic mapping in multiple cell types\",\n      \"pmids\": [\"11401424\", \"11245982\", \"11486273\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No binding partners or signaling pathway identified\", \"Expression restricted to tissue-level surveys without single-cell resolution\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"The first mechanistic function was defined: MS4A4A routes KIT into caveolin-1-enriched endocytic recycling compartments in mast cells, preventing lysosomal degradation and compartmentalizing downstream Akt and PLCγ1 signaling.\",\n      \"evidence\": \"siRNA knockdown in primary human mast cells with endocytic trafficking assays, co-IP with caveolin-1, proliferation and migration readouts\",\n      \"pmids\": [\"25717186\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of caveolin-1 interaction (direct vs. indirect) not resolved\", \"Whether KIT trafficking role extends beyond mast cells untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"MS4A4A was shown to be a general lipid raft organizer for innate immune receptors: it recruits dectin-1 into lipid rafts on macrophages and separately colocalizes with TREM2, establishing two distinct receptor partnerships with different immunological consequences—antifungal/antimetastatic defense and sTREM2 shedding.\",\n      \"evidence\": \"Co-IP and lipid raft fractionation in macrophages; Ms4a4a KO mice challenged with tumor metastasis or dectin-1 ligands; overexpression/knockdown modulating sTREM2 in human macrophages\",\n      \"pmids\": [\"31263276\", \"31413141\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether dectin-1 and TREM2 compete for MS4A4A binding unknown\", \"Structural basis of MS4A4A–receptor interactions undefined\", \"sTREM2 shedding enzyme identity in this context not established\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"MS4A4A was found to selectively potentiate FcεRI signaling—but not MrgprX2—by facilitating PLCγ1 phosphorylation and Orai1-mediated store-operated Ca²⁺ entry, and was placed in the IL-4/Arg1 M2 polarization axis in allergic lung inflammation.\",\n      \"evidence\": \"siRNA in human mast cells with Ca²⁺ flux, degranulation, and lipid raft assays; Ms4a4a KO mice in house dust mite allergy model with Arg1 expression analysis\",\n      \"pmids\": [\"32240745\", \"32589266\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How MS4A4A discriminates FcεRI from MrgprX2 at the molecular level is unclear\", \"Direct mechanism linking MS4A4A to Arg1 transcription not defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"MS4A4A was identified as a driver of M2 tumor-associated macrophage polarization through PI3K/AKT and JAK/STAT6, and its blockade reshaped the tumor immune microenvironment by reducing exhausted T cells and increasing effector CD8⁺ T cells.\",\n      \"evidence\": \"RNA-seq, western blot for PI3K/AKT and JAK/STAT6, antibody blockade and genetic inhibition in subcutaneous and orthotopic mouse tumor models with mass cytometry\",\n      \"pmids\": [\"37507218\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether MS4A4A directly activates PI3K or acts via an upstream receptor not resolved\", \"Therapeutic window and specificity of anti-MS4A4A antibodies in vivo not fully characterized\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A three-part mechanism was delineated: MS4A4A stabilizes MS4A6A, which forms a complex with DAP12 to suppress TREM2; MS4A4A loss or degradation therefore elevates TREM2 and enhances Aβ clearance, with MMP-9 as an additional effector for Aβ degradation, while MS4A4A's cytosolic domain anchors to the cytoskeleton to support phagocytic cup formation and Ca²⁺-dependent engulfment.\",\n      \"evidence\": \"CRISPR KO/OE in macrophages and human microglia, MS4A4A-degrading antibodies in NHP and xenotransplantation amyloid models, co-IP of MS4A6A–DAP12, 5xFAD Ms4a4a KO with in vivo microdialysis, MMP-9 ELISA in mouse and human CSF, cytoskeletal interaction studies, LNP-Il4 rescue\",\n      \"pmids\": [\"41435829\", \"40843775\", \"40349168\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether MS4A4A–MS4A6A interaction is direct or mediated by lipid raft proximity not resolved\", \"Cytoskeletal binding domain within MS4A4A not mapped\", \"Relative contribution of MMP-9 versus TREM2 elevation to Aβ clearance in humans unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"MS4A4A was linked to corticosteroid resistance in macrophages: CS treatment induces MS4A4A, and Ms4a4a deletion enhances the therapeutic response to corticosteroids in experimental arthritis, revealing a pharmacologically relevant immunomodulatory axis.\",\n      \"evidence\": \"RNA-seq and IHC in CS-treated human and murine macrophages; Ms4a4a KO in experimental arthritis with CS treatment\",\n      \"pmids\": [\"40924449\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism by which MS4A4A counteracts corticosteroid action not defined\", \"Whether this extends to other inflammatory diseases unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of MS4A4A's interactions with its diverse receptor partners, the identity of the sheddase responsible for MS4A4A-dependent sTREM2 release, and whether the opposing TREM2 regulatory modes (lipid raft colocalization promoting sTREM2 shedding versus MS4A6A–DAP12-mediated TREM2 suppression) operate simultaneously or in distinct cell states.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No high-resolution structural data for MS4A4A or its complexes\", \"Sheddase identity for sTREM2 in the MS4A4A context unknown\", \"Context-dependent switching between pro-TREM2 and anti-TREM2 functions not experimentally dissected\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [1, 2, 3, 4, 8]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 4, 6, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1, 2, 3, 4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 4, 5, 6, 10, 11]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 4, 6]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CAV1\",\n      \"CLEC7A\",\n      \"TREM2\",\n      \"KIT\",\n      \"MS4A6A\",\n      \"TYROBP\",\n      \"FCER1A\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}